Overview

Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Status:
Recruiting

Trial end date:
2026-12-30

Target enrollment:

Participant gender:

Summary

The purpose of this single arm,phase Ⅱ clinical trail is to determine the safety and efficacy of docetaxel and cisplatin combined with Nimotuzumab in the treatment of recurrent and metastatic nasopharyngeal carcinoma

Phase:

Phase 2

Details

Lead Sponsor:

Sun Yat-sen University

Treatments:

Cisplatin
Docetaxel
Nimotuzumab